Under the terms of an Equipment Hire Agreement, Sanofi has been exploring the utility of Zyoxel’s LiverChip platform. During the project, which commenced in December 2012 and involved the installation of a LiverChip device at a Sanofi research site, the company tested the human hepatocyte LiverChip system against current industry gold standard 2D plated cultures of primary hepatocytes.

 

Using LiverChip, Sanofi’s researchers were able to perform in depth DMPK analyses over much longer time courses of up to 6 days, including the accurate monitoring of dose clearance by the cytochrome P450 enzyme superfamily (CYPs), as well as the induction of CYP isoforms during drug metabolism. The study also confirmed that LiverChip does not suffer from any nonspecific drug binding, while the results exhibited good reproducibility, both within individual plates and between replicate experiments. 

 

As Emma Sceats, chief operating officer of Zyoxel, summarized: “Sanofi have been a very good partner and customer of Zyoxel, and are one of an increasing number of international pharmaceutical companies we are working with. The value proposition of LiverChip’s extended time window is proving especially useful for applications such as assessing low clearance compounds, formation and detection of rare metabolites and to study the impact of chronic multiple dosing. We believe that the system can become part of the routine process for preclinical drug testing, ensuring only high quality candidates are taken through to clinical trials. Ultimately, we hope this will facilitate the production of more effective medicines that exhibit fewer side effects, enhancing the future treatment of patients.”

 

 

Date: December 3, 2013

Source: Zyoxel